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Abstract
Informative genes from microarray data can be used to construct prediction model and investigate biological mechanisms.
Differentially expressed genes, the main targets of most gene selection methods, can be classified as single- and multiple-
class specific signature genes. Here, we present a novel gene selection algorithm based on a Group Marker Index (GMI),
which is intuitive, of low-computational complexity, and efficient in identification of both types of genes. Most gene
selection methods identify only single-class specific signature genes and cannot identify multiple-class specific signature
genes easily. Our algorithm can detect de novo certain conditions of multiple-class specificity of a gene and makes use of a
novel non-parametric indicator to assess the discrimination ability between classes. Our method is effective even when the
sample size is small as well as when the class sizes are significantly different. To compare the effectiveness and robustness
we formulate an intuitive template-based method and use four well-known datasets. We demonstrate that our algorithm
outperforms the template-based method in difficult cases with unbalanced distribution. Moreover, the multiple-class
specific genes are good biomarkers and play important roles in biological pathways. Our literature survey supports that the
proposed method identifies unique multiple-class specific marker genes (not reported earlier to be related to cancer) in the
Central Nervous System data. It also discovers unique biomarkers indicating the intrinsic difference between subtypes of
lung cancer. We also associate the pathway information with the multiple-class specific signature genes and cross-reference
to published studies. We find that the identified genes participate in the pathways directly involved in cancer development
in leukemia data. Our method gives a promising way to find genes that can involve in pathways of multiple diseases and
hence opens up the possibility of using an existing drug on other diseases as well as designing a single drug for multiple
diseases.
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Introduction
Gene selection/biomarker identification methods can be
classified as linear and nonlinear methods [1]. A linear method
assumes that good biomarkers for a class will be highly expressed
(or unexpressed) for that class and unexpressed (or highly
expressed) for the rest of the classes [2,3]. Nonlinear methods
identify biomarkers exploiting both linear and nonlinear interac-
tions between classes and genes [4,5]. Most methods are linear in
nature and there are a few non-linear approaches. Nonlinear
approaches can discover a small set of discriminatory genes that
are good enough for diagnosis of a set of diseases. But the
relationship of biomarkers identified by nonlinear methods with
different classes may not be easily visualized. Saeys et al. [6]
reviewed various methods of biomarker identification and
suggested three categories for the existing methodologies. The
first one is the filter method category, which ranks genes
independently of the classifier that is used. Many linear methods,
either univariate or multivariate, e.g., ‘‘SAM’’ [7], ‘‘shrinkage t’’
[8], ‘‘correlation-adjusted t’’ [9] belong to this category. Most of
these methods are essentially based on Student’s t-test or its
modified/adapted forms. In some cases, in conjunction with the t-
test, authors have used additional procedures to account for the
high-dimensional characteristic of microarray data. In addition to
t-test, SAM also uses Wilcoxon’s Rank Sum test. In this category,
other parametric and non-parametric tests have also been used
[10,11]. The second one is the wrapper method category, which
selects genes according to the predictive performance of the
associated classifier [12-14]. The final category of embedded
methods assigns weights to the importance of genes by making
use of the internal parameters of the classification model – this is
an integrated approach where the feature weighting/selection and
classifier design are done simultaneously. The well-known SVM-
RFE [4], other SVM-based methods, e.g., MMC-RFE [15],
MSVM-RFE [16], SVM-RCE [17], and SVM-RNE [18] all
belong to this category. Also, some neural network-based methods,
e.g., online FSMLP [5], belong to the same category. The
advantages of these wrapper and embedded methods are that they can
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24259capture non-linear interactions between genes as well as
interaction between genes and the diseases. As a result, such
marker genes usually provide a better predictive performance.
Most existing gene selection methods (particularly linear
methods) can identify only single-class specific signature genes
(i.e., genes that are expressed for one class and unexpressed for the
rest of the classes). However, there could be genes which are
expressed for a subset of classes (say, for a subgroup of cancers).
Such genes are biologically informative genes. Unfortunately, we
have failed to locate any study dealing with this important issue.
None of the methods discussed earlier can be used easily to identify
‘‘multiple-class specific’’ marker genes. In principle, it may be
possible to use methods in the filter category, but it will involve
extensive computation. For example, due to the two-class
discriminant nature of statistics, such as t-statistic (that is frequently
used), further strategies, e.g., one-versus-one (OVO), one-versus-all
(OVA), are required to apply these methods in identification of
multiple-class specific marker genes. Consequently, to find useful
biomarkers, a time-consuming procedure considering all possible
combinations of classes has to be performed. Pavlidis and Nobel
have proposed an ANOVA and template matching based
approach [19] to identify such multiple-class specific biomarkers.
But as explained above, to find genes with multiple-class specific
signatures, we need to try all possible combinations of classes,
which would demand considerable computation. Also, another
interesting but time consuming procedure has been proposed in
[20] to assign significance to statistically defined expression
patterns.
On the other hand, for methods in the embedded and wrapper
categories, although we can get better predictive performance,
the interactions between the biomarkers and the diseases may not
be easy to interpret/understand due to the non-linear nature of
interactions. Moreover, to get multiple-class specific biomarkers,
we shall still require some post-processing, which may not be
easy. Finally, there may be some biomarkers for some specific
groups of diseases, but such a method may not recognize/identify
those because such methods are driven by minimization of
classification error. Hence, there is a need for developing
methods/algorithms that can find genes with multiple-class
specific signatures.
Here we propose a novel gene selection index, Group Marker
Index (GMI), which can identify de novo in a single process both
single- and multiple-class specific signature genes (both are called
group specific genes). It is computationally efficient in the sense
that it does not require computation of the index for all possible
subsets of classes. For a K-class data set, GMI is evaluated K-1
times rather than for 2
K-2 combinations. GMI is a distribution-free
method, which shares the advantage of non-parametric methods
and is not influenced by the lack of knowledge about the
distribution of data. Furthermore, we use GMI with a repeated
random sampling procedure to select candidate marker genes in a
more reliable manner. Here a permutation procedure is used to
assess the significance of selected marker genes. We have used four
multiple-class microarray data sets, which are Small Round Blue
Cell Tumors (SRBCT) [21], Leukemia [22], Central Nervous
System (CNS) [23], and Lung Cancer [24], to demonstrate the
effectiveness of the proposed method. We demonstrate that genes
identified by the proposed scheme participate in several important
biological processes. Scatter-plots of the identified group specific
genes for these data sets also exhibit good discriminating power
among classes. Although we could not find any method in the
literature addressing this problem, just for the sake of comparison,
we have proposed and used an algorithm using a template-based
gene selection scheme.
Results
Significance of genes selected by using GMI
In this study, we develop a gene evaluation index named
‘‘Group Marker Index (GMI)’’, to select biologically significant
genes for both two- and multiple-class cancer discrimination
problems. Given expression profiles on K different types of cancers
(diseases), our GMI-based algorithm tries to discover subsets of the
cancers/diseases, if present, that can be discriminated from the
remaining ones using gene expressions, as well as, the discrimi-
natory genes. If a gene is highly expressed for a subset containing n
classes (n=1,2,…,K-1) compared to the remaining (K-n) classes,
then we call that gene a level-n discriminatory gene. This set of
cancer classes with higher expression values is called the ‘‘upper
group’’. On the other hand, the set of remaining classes with lower
expression values is called the ‘‘lower group’’. The GMI algorithm
finds, all level-n (n= 1 ,2 ,… ,K-1) genes, if exist. The detailed
description of the algorithm is provided in the Materials and Methods
section.
The quality of genes selected by using GMI is demonstrated
here in two significant ways. First, for each of the four data sets, we
present visual assessments of the quality of the top most level-n
gene for every level-n selected by GMI. We use a scatter-plot to
show the distribution of gene expression values for the top most
level-n gene. For the scatter-plot the y-axis expresses the observed
gene expression values (normalized in [0,1]) and the x-axis
indicates the number and identification of samples in a data set.
The samples in different classes are represented by different
symbols and colors, which help illustrate the discriminating power
of (each) individual GMI-selected gene. For example, each sub-
panel in Fig. 1 and Figs. S1, S2, S3 displays a top most level-n gene
for different level n in the different data sets. As expected, each
such gene appears with high gene expression values in the samples
from n classes (i.e., the upper group, infra at Computation of GMI),
but with low gene expression values in the samples of the
remaining classes/subgroups (i.e., the lower group). Also, every top
most level-n gene demonstrates good separation and low overlap
between samples belonging to upper and lower groups.
In addition, we have further tabulated (Table 1 and Tables S1,
S2, S3) the following basic information for the top 10 genes, which
are individually selected using GMI from each level of discrim-
ination: probe name, official gene symbol, class-labels in upper
group and lower group, frequency of appearance of the gene in the
list of top 10 genes, averaged GMI value, p-value and q-value
obtained from the permutation test mentioned in the Materials and
Methods section. These tables further provide us with several
interesting conclusions: (a) We find that all GMI-selected genes
have very low p- and q-values (in many cases it is so low that it is
represented as zero) suggesting that these genes carry statistically
significant multiple-class specific signatures. (b) For a given level of
discrimination, the genes with quite high GMI values and
appearing with high frequencies are considered better group-
specific biomarkers. (c) We use the GMI value to represent a
measure of discrimination for a gene between upper and lower
groups. Thus, a gene with a higher GMI value implies its higher
discriminating power between upper and lower groups. This
information can be used for comparison of discriminating power
of genes at different levels in the same data set. As demonstrated
by the GMI values in Table 1 for the SRBCT data set, the
discriminating power of level-2 genes is weaker than that of level-3
genes, and the discriminating power of level-3 genes is weaker than
that of level-1 genes. Also as shown by the GMI values set forth in
Table S3 for the Lung Cancer data set, the discriminating power
of level-3 and level-4 genes is weaker than that of level-1 and level-
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scatter-plot of the top most gene of each level for all data sets (Fig. 1
and Figs. S1, S2, S3). For example, WAS, the top most level-1 gene
in the SRBCT data set, has a GMI value of 2.98 which is higher
than the GMI value, 1.02, of PTPN12, the top most gene of level-2
in the same data set. From Fig. 1, we can observe that the
discriminating ability of the WAS gene is much stronger than that
of the PTPN12 gene because the WAS gene has no overlapped
sample between upper and lower groups, whereas the PTPN12
gene has some overlapped samples. Hence, the visual illustration
of the top most genes is consistent with the corresponding GMI
values. (d) The GMI values can provide an objective assessment of
the discriminating power even between data sets. For example,
VAMP2, the top most level-1 gene in the Lung Cancer data set, has
Figure 1. Scatter-plots of the top most gene of each level in the SRBCT data set. Panels (a), (b) and (c) are the scatter-plots of the top most
gene of level-1, level-2, and level-3, respectively. The top most genes are WAS (236282), PTPN12 (774502) and GSTA4 (504791), respectively. There are
four classes in the SRBCT data set: Ewing sarcomas (EWS), Burkitt lymphomas (BL), neuroblastomas (NB), and rhabdomyosarcomas (RMS).
doi:10.1371/journal.pone.0024259.g001
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even stronger than WAS, the top most level-1 gene in the SRBCT
data set. Figure 1 and Figure S3 also reveal the stronger
discriminating power of VAMP2 over WAS because VAMP2 also
has no overlapped samples between upper and lower groups, and
gets a bigger numerator for computing GMI (a higher value of the
closest separation between a class in the upper group and a class in
the lower group; i.e., the difference between the mean values of
classes Cn(s) and Cn+1(s),o rmSep = mn(s) – mn+1(s) in Eq. (1) mentioned
in the Materials and Methods section). Our results demonstrate that
GMI is very effective in identifying group-specific marker genes
with clear discriminating power and we could obtain a robust list
of candidate genes by conducting the repeated random splitting
procedure.
In addition, the conventional biomarkers for cancers are usually
the level-1 genes with single tissue specific expression patterns. The
protein products of those marker genes are usually receptors or
proteins expressed in the cell surface. GMI can also identify the
known biomarkers. For example, FGFR4, the level-1 gene highly
expressed in rhabdomyosarcomas (RMS) class, is ranked within
the top 10 level-1 genes in the SRBCT data set (Table 1). Multiple
studies have reported that FGFR4 is highly expressed in RMS [25-
27] and the mRNA expression level of FGFR4 is correlated with its
protein level [25,26,28]. Furthermore, it has been shown that
mutationally activated FGFR4 acts as an oncogene [29]. Another
level-1 gene ranked within the top 10 for the SRBCT data set,
CD99, is highly expressed in Ewing sarcomas (EWS) class. It has
been reported that CD99 is highly expressed in all EWS and the
engagement of CD99 with anti-CD99 monoclonal antibodies
would induce massive apoptosis as well as reduce malignant
potential of EWS cells [30]. The deletion of CD99 expression in
human EWS cell lines would reduce their abilities of tumorigenesis
and metastasis [31]. Moreover, the engagement of CD99 improves
the efficiency of the conventional chemotherapeutic agents and
reduces tumor growth along with a significant delay of metastasis
[32]. These are some of the examples to demonstrate that GMI is
capable of identifying the known biomarkers as well as the special
type of group biomarkers.
Table 1. Summary of top 10 genes of each level selected by GMI in the SRBCT data set.
Level Probe ID Gene Symbol Upper Group Lower Group Freq. Ave. GMI value p-value q-value
1 236282 WAS 2 143 100 2.98 0 0
770394 FCGRT 1 432 99 4.98 0 0
241412 ELF1 2 143 91 2.45 0 0
814260 FVT1 1 234 76 3.65 0 0
377461 CAV1 1 432 57 2.37 0 0
784224 FGFR4 4 213 53 2.43 0 0
812105 MLLT11 3 412 52 2.57 0 0
1435862 CD99 1 432 50 2.14 0 0
183337 HLA-DMA 2 413 42 1.78 0 0
796258 SGCA 4 231 37 2.02 0 0
2 774502 PTPN12 34 12 95 1.02 0 0
365826 GAS1 14 32 75 0.80 0 0
784593 RND3 34 12 72 0.75 0 0
812965 MYC 21 43 64 0.72 0 0
789182 PCNA 23 41 54 0.64 0 0
859359 TP53I3 43 12 44 0.62 0 0
714453 IL4R 42 13 38 0.57 2.17E-06 2.17E-06
82903 (EST) 21 43 37 0.54 2.17E-06 2.17E-06
159455 PLD3 41 32 34 0.53 2.17E-06 2.17E-06
308163 YAP1 41 32 32 0.53 2.17E-06 2.17E-06
3 897164 CTNNA1 134 2 100 1.40 0 0
504791 GSTA4 314 2 100 1.89 0 0
897788 PTPRF 134 2 100 1.40 0 0
295985 CDK6 342 1 86 1.52 0 0
810057 CSDA 142 3 69 1.19 0 0
21652 CTNNA1 143 2 61 0.85 0 0
51320 DBNDD1 341 2 50 0.73 0 0
212542 PBX1 143 2 48 0.59 0 0
813742 XPO6 341 2 38 0.80 0 0
741831 PLTP 143 2 28 0.54 2.17E-06 2.17E-06
Ewing sarcomas (EWS), Burkitt lymphomas (BL), neuroblastomas (NB), and rhabdomyosarcomas (RMS) are represented as Group 1 to Group 4 in order.
doi:10.1371/journal.pone.0024259.t001
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For a fair comparison of our GMI method with the existing
methods for similar purpose, we have selected the most widely
used template-matching based method and adapted it using the
same iterative procedure as followed for GMI. We call this method
as the template-based method (TBM). The detailed steps of the
template-based method are described in the Materials and Methods
section. First, we have used TBM to select group specific genes in
the SRBCT and CNS data sets. Although, for the CNS data set,
GMI can identify good level-2 discriminatory genes, it cannot
identify good level-2 discriminatory genes for the SRBCT data set
(please refer to Table 1 and Table S2). So for the SRBCT data set
we want to check if there are useful level-2 discriminatory genes
and GMI cannot identify those. For the CNS data set, we want to
check whether GMI has already found good level-2 and level-3
discriminatory genes. In other words, we want to check if TBM
can identify better genes. For each case, we have compared the top
10 genes identified by GMI and TBM.
Comparing the top 10 level-2 genes in the SRBCT data set
(Table 2), we find that both GMI and TBM select PTPN12
(774502) as the top most gene. Therefore, there may be no better
level-2 gene in the SRBCT data set. To further check whether
GMI miss any good level-2 gene, we focus on those genes which
are identified by TBM but not by GMI. Between the two gene
lists, there are four common genes. With a careful inspection of
scatter-plots of the TBM-selected unique genes, we find that for
each of such genes there is a substantial overlap between the upper
and the lower groups. For a few of the GMI-selected unique genes,
a similar situation arises. Thus to make a better objective
evaluation of the two lists, for each gene in Table 2, we have
performed a leave-one-out cross validation (LOOCV) with the
nearest neighbor classifier (NNC), which enables us to assess the
discriminating power of each gene for the two groups of diseases.
The resultant accuracies are tabulated in the last column of
Table 2. On the average, the GMI-selected unique genes are
superior to the TBM-selected unique genes. One GMI-selected
unique gene, Probe ID = 365826 (ranked the second by GMI)
achieves the highest accuracy of 0.9048! On the other hand, Probe
ID = 841620, which is ranked the second and selected only by
TBM, achieves the least accuracy of 0.6508! This suggests that
GMI selected genes are better discriminator; however, as we have
mentioned earlier, finding genes suitable for designing classifiers is
not the objective of this study.
Table S4 reveals that for the CNS data set in the lists of top 10
level-2 genes identified by GMI and TBM there are 8 common
genes; while for the level-3 genes there are 5 common genes (Table
S5). Most of the genes common to both methods are on the top of
the TBM gene list. These findings imply that there may not be
better level-2 and level-3 discriminatory genes in the CNS data set.
Also, the higher agreement between the gene lists identified by
GMI and TBM in this data set with more balanced distribution of
number of samples over classes may indicate that difference in
sample sizes between classes can affect the gene selection.
To investigate the effect of variation of sample sizes between
classes, we have compared the gene lists produced by GMI and
TBM on Leukemia and Lung Cancer data sets. All classes in the
Leukemia data set have comparable sample size. On the other
hand, the Lung Cancer data set has one class with a relatively
large sample size. We compare the top 10 genes for these two data
sets. For the Leukemia data set, considering the level-2 genes we
find that seven of the top 10 genes are common in the two lists.
Moreover, both lists have the same genes at the top (Table S6).
This high percentage of common genes in the two lists might be
taken as an indicator that TBM would identify genes similar to
those identified by GMI in cases where there is not much variation
between sample sizes from different classes.
For the Lung Cancer data set, we consider both level-2 and
level-3 discriminatory genes. In the case of level-2 genes, we have
three common genes in the top 10 genes identified by GMI and
TBM (Table S7). In order to assess the quality of the genes
identified by GMI and TBM, we have compared the scatter-plots
of those genes, which are identified by only one of the methods. A
Table 2. The comparison of top 10 level-2 genes selected by GMI and TBM in the SRBCT data set.
Probes GMI Mean Order GMI Rank GMI Freq. TBM Rank TBM Template TBM Freq. LOOCV NNC Acc.
774502 (34)(12) 1 95 1 (34)(12) 83 0.8413
365826 (14)(32) 2 75 33 (14)(23) 7 0.9048
784593 (34)(12) 3 72 19 (34)(12) 16 0.7778
812965 (21)(43) 4 64 4 (12)(34) 65 0.7143
789182 (23)(41) 5 54 5 (23)(14) 50 0.8730
859359 (43)(12) 6 44 13 (34)(12) 25 0.8889
714453 (42)(13) 7 38 8 (24)(13) 40 0.7460
82903 (21)(43) 8 37 32 (12)(34) 7 0.7460
159455 (41)(32) 9 34 22 (14)(23) 12 0.8254
308163 (41)(32) 10 32 24 (14)(23) 11 0.7302
841620 (13)(42) 12 27 2 (13)(24) 77 0.6508
789204 (23)(41) 16 21 3 (23)(14) 71 0.7460
841641 (13)(42) 11 28 6 (13)(24) 47 0.7778
809557 (23)(14) 18 17 7 (23)(14) 40 0.7460
782811 (23)(14) 33 6 9 (23)(14) 36 0.6984
47542 (23)(41) 15 22 10 (23)(14) 35 0.7460
TBM: Template-based method.
Ewing sarcomas (EWS), Burkitt lymphomas (BL), neuroblastomas (NB), and rhabdomyosarcomas (RMS) are represented as Group 1 to Group 4 in order.
doi:10.1371/journal.pone.0024259.t002
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identified only by TBM are not better genes than those identified
only by GMI for the purpose of discrimination (see File S1).
Furthermore, TAGLN3 (32650_at), which is ranked by GMI as the
top most level-2 gene with the highest frequency of selection, is not
in the top 10 gene list selected by TBM. But the scatter-plot of
TAGLN3 (Figure S3b) reveals that it is definitely a good level-2
gene. Concordant results are also revealed by the single gene
LOOCV accuracy as depicted in Table S7, where TAGLN3
achieves the perfect accuracy. While comparing the level-3
discriminatory genes, we have found that there are three common
genes between the lists of top 10 genes identified by GMI and





selected by TBM appear much like level-2 genes (see Figs. 2a-d).
The top sixth and eighth genes selected by TBM appear more like
level-1 genes (see Figs. 2e–f). Unlike genes selected by TBM, the
scatter-plots of the top genes identified by GMI reveal that these
genes are good level-3 discriminatory genes. On the average, the
single gene LOOCV accuracies of GMI-selected unique genes are
higher than the accuracies of TBM-selected unique genes.
We find that when the class sizes are balanced, more genes are
found common in the top 10 level-n genes produced by GMI and
TBM. When the class sizes are widely different, the lists of top 10
level-n genes are significantly different. And GMI is found to
identify better discriminatory genes. A natural question arises,
why? A possible reason for this may be the fact that correlation
value for a gene with the designated template (used in TBM) is
quite sensitive to the relative sizes of different classes in the training
data. For example, even if the sizes of different classes remain the
same, but the number of samples from one class keeps on
increasing, the correlation value exhibit a monotonic behavior.
This is illustrated in Fig. 3. Suppose in a K-class problem, class 1
has n1 samples, class 2 has n2 samples and the remaining classes
together have n3 samples. Suppose for a gene g, all samples from
class 1 and 2 are highly expressed (with gene expression value of
1), while for the other classes the gene g is unexpressed (i.e., the
gene expression value is zero). In this case, the correlation for the
gene g with the ideal vector for class 1 (the ideal vector will have
expression of 1 for class 1 and 0 for all other classes) will be ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1|n3=½(n1zn2)(n2zn3)
p
 . It can be easily seen that as n3
increases with more and more unexpressed samples keeping the





. The filled circle in Fig. 3
illustrates this when n1=60, n2=15 and n3 varies from 20 to 300.
Note that, when n3=20, the correlation value is 0.68 but that
increases to 0.85 when n3 becomes 140, although neither the
expression profiles for class 1 and class 2 change nor the expression
profile of the remaining classes changes, and for a multiple-class
Figure 2. The level-2-like and level-1-like genes ranked within top 10 level-3 genes by template-based method in the Lung Cancer
data set. Panels (a), (b), (c) and (d) are the scatter-plots of the level-2-like genes. Panels (e) and (f) are the scatter-plots of the level-1-like genes.
doi:10.1371/journal.pone.0024259.g002
Group Biomarker Identification
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24259data 140 is not a big number. Thus, the template-based method,
which selects genes based on correlation value, sometimes is not
sensitive enough to reflect the desired behavior of samples. This
will lead to improper ranking.
Following the same experimental design, we add one extra class
(class (K+1)) with only five samples, which is either up-regulated or
down-regulated. The template is so set that samples in class 1 and
class (K+1) are highly expressed while unexpressed in the
remaining classes. When class (K+1) is up-regulated, the tendency
of the resultant correlation values (shown by the symbol ‘‘+’’ in
Fig. 3) is almost the same as that of the K-class case. In case, class
(K+1) is down-regulated, the nature of the resultant correlation
values (shown by triangles in Fig. 3) is still similar to the previous
two cases with correlation values in a slightly lower region. In these
two (K+1)-class cases, most samples are unexpressed, which are
contributed by the pool (class 3 to class K) with n3 samples.
Therefore, it has practically no effect when we set class (K+1) up-
regulated. On the other hand, there is a little influence when class
(K+1) is down-regulated. However, as the number of samples
increases, the impact becomes less and less.
The level 2-like genes selected by TBM in the Lung Cancer data
set (Figs. 2a–d) are good examples to show that this effect indeed
happens in real data. All of those four genes are selected based on
the template with high expression for classes 2, 3, and 5 (please
refer to Table S8). However, the Lung Cancer data set is quite
unbalanced in the number of samples between different classes.
There are only six samples for class 3, which contributes a little in
computing the correlation value of TBM (only four samples are
randomly selected during the repeated random splitting proce-
dure). Therefore, irrespective of whether class 3 is highly expressed
or unexpressed, the contribution of class 3 in correlation may not
be significant (Figs. 2b–d). Even for class 2 (Normal) which has 17
samples, the selection by TBM suffers from the same problem
(Fig. 2a). Similarly, the level 1-like genes (Figs. 2e–f) can also
support this effect.
Biological Relevance of some level-2 and level-3
biomarkers
CNS data set. The first 4 genes in level-2 are highly
expressed in human cerebellar tumors and malignant glioma
(i.e., Ncer and MGlio; upper group representing 4 and 2) and are
practically unexpressed in the rest of the classes (lower group
consisting of 1, 3 and 5). Interestingly, six of the top genes in level-
2( PRUNE2, TIMP4, TMOD1, ADORA1, NEUROD1 and C1orf61/
Croc4) with GMI score ranging from 2.38 to 1.17 are primarily, if
not solely, involved in cytoskeleton maintenance. Perturbation in
the expression levels of these genes is likely to affect morphological,
structural and functional integrity of the cell. For example,
PRUNE2 gene is over-expressed in prostate cancer and down-
regulates Rho-A and Rho-C that are involved in actin
polymerization and oncogenic transformation [33,34]. TIMP4
inhibits tumor progression by inhibiting cell matrix degradation by
endopeptidase MMP-2 [35]. TMOD1 regulates actin filament
dynamics [36]. On the other hand, C1orf61/Croc4 positively
controls c-fos activity and the later one up-regulates actin
expression [37,38]. Moreover, NEUROD1, a transcriptional
factor, controls transcription of cytoskeletal genes [39]. In
cancer, one of the frequently affected pathways is the
Figure 3. Effect of sample size on Pearson’s correlation coefficient values.
doi:10.1371/journal.pone.0024259.g003
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are dys-regulated but not necessarily mutated. For example, cofilin
expression is frequently increased in glioblastoma and ovarian
cancer [40,41] whereas cortactin is often over-expressed in breast
cancer and squamous carcinoma of head and neck [42,43].
Literature search revealed that none of the level-2 genes are ever
mutated in any cancer but rather work to protect the cytoskeletal
integrity of the cell. Over-expression of these genes in human
cerebellar tumors and malignant glioma may reflect as an innate
attempt of the cell to counteract the process of tumor
transformation.
Earlier we proposed GDI system (Gene Dominant/Dormant
Index) that selects two specific types of gene, i.e., dominant and
dormant genes wherein the former is up-regulated in one specific
class and down-regulated in the remaining classes, and the latter is
down-regulated in one specific class but up-regulated in the rest of
the classes [1]. Although different cancers, according to their tissue
of origin, do differ in their mode of action through regulation and/
or dys-regulation of various physiological pathways, they do also
share some common genes/pathways in the formation of cancers.
In that sense, GMI-discovered genes that are up-regulated in more
than one-class of cancer (here we can also termed them as co-
dominant) may provide additional biological insights of how various
cancers might be related and probable molecular pathways
involved in them.
In case of the level-3 genes, it appears that they are functionally
diverse. However, the first two genes share a common cytoskeletal
pathway. For example, FEZ1 (GMI score 3.95), highly expressed
in the group {4, 2, 5}, is a brain specific cytoskeletal regulatory
protein associated with microtubule and in various tumors it is
either deleted and/or mutated [44]. But here in malignant glioma,
human cerebellar tumor and primitive neuroectodermal tumor
(PNET) the expression of FEZ1 is increased signifying a failed
attempt of the cell to contain the tumor growth. Recent study
shows that FRG1 (GMI value 2.07, up-regulated in group {1, 4,
3}) a multifunctional protein, specially binds to F-actin and its
misregulation leads to facioscapulohumeral muscular dystrophy
(FSHD) [45]. HMGN2 with GMI value of 1.11 (up-regulated in
group {1, 3, 5}) is a highly conserved nucleosomal protein
involved in unfolding higher-order chromatin structure and acts as
an impediment for cell migration [46,47]. VAT1 with GMI value
of 1.14 (up-regulated in group {3, 1, 2}) controls the storage and
release of neurotransmitters in the nerve terminal [48]. Impor-
tantly, none of these top-5 genes in both level-2 (except PRUNE2)
and level-3 are ever reported as biomarkers (over-expressed and/
or under-expressed) for any type of cancer. In that sense, our
analysis demonstrates that these co-dominant genes may be used as
unique signature genes in defining the respective tumor groups.
Lung Cancer data set. Level-2 and level-3 discriminatory
genes in the Lung Cancer data set are quite interesting. As in the
case for CNS data set, the four top level-2 discriminatory genes
with GMI values ranging from 3.45 to 1.58 are primarily involved
in regulation of cytoskeleton that controls vesicular trafficking in
golgi bodies [49]. These genes are basically co-dominant in classes 5
and 3, representing pulmonary carcinoids (COID) and small cell
lung cancer (SCLC), respectively. TAGLN3 associates with and
regulates F-actin, a-tubulin, tau and MAP2 [50]. CRMP1 is a
phosphoprotein and controls microtubules [51]. NCAM1 is a
classical cell adhesion molecule that interacts with a number of
cytoskeletal proteins and regulates cell architecture. INSM1 gene
encodes a zinc finger DNA-binding domain and a putative
prohormone domain. This gene is a sensitive marker for
neuroendocrine differentiation of human lung tumors [52].
Interestingly, INSM1 acts as a transcriptional repressor of
NEUROD that is involved in regulating cytoskeleton genes [53].
It is important to note that four of the first five genes in level-2
(TGLN3, CRMP1, NCAM1 and SCAMP5) are supposed to be
neuron-specific [54-57]. But our analysis shows that these neuron-
specific genes are aberrantly expressed in COID and SCLC class
of lung tumor, most likely as a result of mis-functioning of SWI/
SNF complex [58]. The fact that the top 4 level-2 discriminatory
genes both in CNS and Lung Cancer data sets are involved in the
same molecular pathway might be a pure coincidence or else it
could be that pathways of cancer, irrespective of types, are
frequently involved dys-regulating genes associated with
cytoskeleton architecture.
On the other hand, the top 6 level-3 discriminatory genes are
basically involved in calcium signaling; however, they bear quite a
low GMI values ranging from 1.25 to 0.34. These genes, except
SEC14L1, are primarily co-dominant in the classes 4, 1 and 2, i.e.,
squamous cell carcinomas (SQ), lung adenocarcinomas (Adeno)
and normal lung (Normal). S100A11 and S100A10 are calcium
binding proteins and their increased expression are often observed
in colorectal and prostate cancer, including non-small cell lung
cancer [59,60]. VAMP8 is involved in calcium-dependent
exocytosis process and SEC14L1 is a membrane trafficking
protein, and none of them is linked to cancer pathways. On the
other hand, LGALS3, an IgE-lectin binding protein, is often
abundantly expressed in thyroid cancer, hepatocellular carcinoma
and in non-small cell lung cancer [61,62]. FAM38 is involved in
intracellular calcium release [63]. Calcium signaling plays very
important role in cancer in mediating angiogenesis steps such as
invasion, adhesion and tumor cell migration. In many cancers,
calcium signaling genes are up-regulated. The fact that the
aforementioned genes are also up-regulated in normal lung (class
2) indicates that intact calcium signaling pathway may be
necessary for tumorigenesis process in these cancer subgroups.
In a nutshell GMI method establishes that cytoskeleton
regulating genes are aberrantly expressed in pulmonary carcinoids
(COID) and small cell lung cancer (SCLC) whereas calcium
signaling pathway genes are active in the rest of the classes, i.e.,
squamous cell carcinomas (SQ), adenocarcinomas (Adeno), and
normal lung (Normal).
Typical microarray data analysis finds markers that can
differentiate one class of cancer from the others, while GMI can
find markers, which exhibit similar expression pattern in a group
of cancers and can distinguish one group of cancers from another
group of cancers. Thus, the importance of our GMI algorithm is in
identifying de novo group specific genes in an automatic manner.
When we have samples from multiple cancers/diseases with less
knowledge about the relationship between them, GMI could be
very useful to discover a group (subset) of cancers, if exists, that can
be discriminated from the remaining set of cancers using
expression pattern of one or more genes. This in turn can help
us to understand the relationship between subsets of cancers/
diseases groups via functional analysis of the GMI-identified group
specific genes. Further, existence and discovery of such group
markers open up the possibility of finding common drug targets for
different diseases as well as possibility of using drugs designed for
one disease to cure another disease.
KEGG pathway analysis
After analyzing the relationship between a single gene and
multiple diseases, we attempt to explore the relationship between
the groups of discriminatory genes and diseases. For this, instead of
considering level-1 discriminatory genes, which may be identified
by all gene selection methods, we focus on the level-2
discriminatory genes first. We try to identify related biological
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cross-referencing to the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database [64-66].
We take the advantage of the abundant number of genes in the
Leukemia and Lung Cancer data sets in the data selection for
pathway analysis. For the Leukemia data set, we consider all level-
2 genes with p-values smaller or equal to 0.0001. Subsequently, we
divide these level-2 genes into three different gene lists based on
the composition of the upper group. The numbers of genes,
actually probe sets, in each list were: 712 for the upper group
composed of acute lymphoblastic leukemia (ALL) and mixed-
lineage Leukemia (MLL), which we call ALL-MLL list; 3 for the
upper group composed of ALL and acute myelogenous leukemia
(AML), which is termed as ALL-AML list; 100 for the upper group
composed of MLL and AML (MLL-AML list). Next, we use the
functional annotation tool provided by the database for annota-
tion, visualization and integrated discovery (DAVID ver. 6.7)
[67,68] to cross-reference to the KEGG database (accepted default
parameters).
For the ALL-MLL list, 709 probe sets that belong to Homo
sapiens, are selected and the default background is used for the
analysis. A total of 665 DAVID IDs are converted and 228 probe
sets are involved in the KEGG pathway category. The output
results provided by DAVID are summarized in Table 3. The
identified pathways/annotation terms are tabulated in the first
column (Term). The total number of genes (Count) and the
corresponding percentage (%) in our gene list involved in each
pathway along with the modified Fisher Exact p-value (p-value),
and other enrichment quantitative measurements (Fold Enrich-
ment, Bonferroni, Benjamini, FDR) are also included in Table 3.
As shown in Table 3, there are four pathways with EASE Score,
the modified Fisher Exact p-value, smaller than 0.01. These are
spliceosome, B-cell receptor signaling, basal transcription factors
and inositol phosphate metabolism pathways. Literature search
revealed that these pathways are often impaired in ALL and MLL
development [69–73]. On the other hand, if we consider EASE
Score smaller than 0.05, then 15 pathways are identified. The full
table with probe set lists is provided in Table S9. Most of these
additional pathways are involved in cancer as evident by their
name such as colorectal cancer pathways, base excision repair,
mismatch repair, nucleotide excision repair, and more specifically
involvement of chronic myeloid leukemia pathway is noteworthy.
Interestingly, pathways like fatty acid metabolism, phosphatidy-
lionositol signaling and ubiquitin mediated proteolysis that at first
Table 3. Summarization of the identified pathways related to the level-2 discriminatory genes in the Leukemia data set.
Term Count % p-value Fold Enrichment Bonferroni Benjamini FDR
ALL-MLL List
hsa03040:Spliceosome 21 3.1579 5.38E-07 3.7171 8.23E-05 8.23E-05 6.44E-04
hsa04662:B cell receptor
signaling pathway
14 2.1053 2.13E-05 4.1632 0.0033 0.0016 0.0256
hsa03022:Basal transcription factors 7 1.0526 0.0040 4.4605 0.4623 0.1868 4.7433
hsa00562:Inositol phosphate metabolism 8 1.2030 0.0095 3.3041 0.7685 0.3064 10.8272
hsa05210:Colorectal cancer 10 1.5038 0.0120 2.6551 0.8413 0.3080 13.4271
hsa03420:Nucleotide excision repair 7 1.0526 0.0126 3.5481 0.8565 0.2765 14.1065
hsa04910:Insulin signaling pathway 13 1.9549 0.0168 2.1477 0.9248 0.3091 18.3459
hsa03430:Mismatch repair 5 0.7519 0.0175 4.8484 0.9333 0.2871 19.1067
hsa05220:Chronic myeloid leukemia 9 1.3534 0.0178 2.6763 0.9363 0.2636 19.3979
hsa03410:Base excision repair 6 0.9023 0.0184 3.8233 0.9419 0.2477 19.9781
hsa05340:Primary immunodeficiency 6 0.9023 0.0184 3.8233 0.9419 0.2477 19.9781
hsa04660:T cell receptor
signaling pathway
11 1.6541 0.0216 2.2716 0.9646 0.2620 23.0243
hsa00071:Fatty acid metabolism 6 0.9023 0.0312 3.3454 0.9922 0.3327 31.6244
hsa04120:Ubiquitin mediated proteolysis 12 1.8045 0.0414 1.9535 0.9985 0.3923 39.7743
hsa04070:Phosphatidylinositol
signaling system
8 1.2030 0.0459 2.4111 0.9992 0.4014 43.0280
MLL-AML List
hsa05221:Acute myeloid leukemia 4 4.4944 0.0055 10.6270 0.3252 0.3252 5.5876
hsa04662:B cell receptor
signaling pathway
4 4.4944 0.0112 8.2182 0.5520 0.3307 11.0767
hsa04664:Fc epsilon RI
signaling pathway
4 4.4944 0.0125 7.9021 0.5909 0.2577 12.2495
hsa04062:Chemokine
signaling pathway
5 5.6180 0.0285 4.1201 0.8715 0.4013 25.9129
The contents of Tables 3-5 are the output results provided by DAVID. The first column (Term) contains the identified KEGG pathways. The second column (Count)
indicates the total number of genes in our gene list which is involved in each pathway. The third column (%) shows the same information as shown by the second
column but using percentage. The following columns (p-value, Fold Enrichment, Bonferroni, Benjamini, FDR) represent the modified Fisher Exact p-value and other
enrichment quantitative measurements, respectively. For more detailed information, please refer to DAVID[67,68].
doi:10.1371/journal.pone.0024259.t003
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indeed found to be very much molecularly involved in the
pathogenesis of ALL and MLL as revealed by literature search
[74–77].
Using the same procedure, 98 probe sets belonging to Homo
sapiens and one probe set belonging to Mus musculus are selected for
the MLL-AML list. These probe sets are mapped to 89 DAVID
IDs and only 33 probe sets are involved in the KEGG pathway
category. Befitting our method of analysis, the only pathway
identified by the functional annotation tool with EASE Score
smaller than 0.01 is the Acute Myeloid Leukemia pathway
(KEGG entry ID: hsa05221). This attests that our method of
analysis may be relevant in identifying the gene(s) signatures for
distinguishing subtypes of cancer. Additional three pathways, B
cell signaling, Chemokine signaling and Fc epsilom R1 signaling,
which have passed the EASE Score criterion (p-value , 0.05) are
also shown in the Table 3. These are all well documented
pathways that are impaired in AML and/or MLL cancer [78-80].
Moreover, MLL is a special ALL group, which carries MLL gene
translocation. The authors of the Leukemia data set [22] collected
ALL and MLL samples from the individuals diagnosed as CD19
+
B-precursor ALL without and with MLL translocation, respec-
tively. Those well-known B cell marker genes, e.g., CD19, CD81,
CD79A, CD79B, are all contained in the ALL-MLL list. Some
other genes, which have been discussed by the authors [22] e.g.,
IL7R, DNTT, TCF3, POU2AF1 and SMARCA4, are also listed in
the ALL-MLL list. The rest of genes in the ALL-MLL list are
related to B cell proliferation, phosphorylation, DNA replication,
tumor development. On the other hand, the myeloid-specific
genes e.g., CCNA1, SERPINB1, RNASE3, and some other genes
that are discussed by the authors who published the data set e.g.,
CD44, HOXA9, HOXA5, SPN, LGALS1, ANXA1, ANXA2, are
contained in the MLL-AML list. The only three genes exhibiting
common up-regulated pattern in ALL and AML are RYK,
SCHIP1, and YESP1. The long list of level-2 discriminatory genes
for the ALL and MLL group suggests that between the three
classes, the ALL and MLL group share more similar physiological
properties. MLL represents mixed-lineage features yet we can find
some similarities between MLL and AML. However, ALL and
AML are distinguished from each other. In a nutshell, many of the
level-2 discriminatory genes identified in our analysis for leukemia
class-specific signatures are directly involved in pathways that lead
to the development of leukemia. We believe that GMI would be
helpful in understanding the relationship between unknown
classes.
Furthermore, we find that the B cell receptor signaling pathway
was identified by both ALL-MLL list and MLL-AML list from
Table 3. To further investigate this pathway, we downloaded the
figure of this pathway from KEGG [64–66] and labeled the level-2
genes using the same principle as used by DAVID [67,68]. The
modified figure is shown in Fig. S4. In Figure S4, those genes,
which are relatively up-regulated in the ALL-MLL group, are
labeled with red stars. On the other hand, those genes, which are
up-regulated in MLL-AML group, are labeled with blue stars. We
may interpret those red star genes as lymphoblastic genes because
of the relatively up-regulated expression in both ALL and MLL
but down-regulated expression in AML. Subsequently, those blue
star genes can be treated as myelogenous genes because of their
relatively lower expression in ALL. As summarized by KEGG
[64–66], the activation of this pathway will involve in B cell
proliferation, differentiation and Ig production as well as other
processes. Thus, we find that many genes involved in this pathway
are labeled with red stars (highly expressed in the CD19
+ B-
precursor ALL and MLL). We may interpret that the activation of
CD79A (Iga) and CD79B (Igb) with the co-simulators CD81 and
CD19 triggers the activation of B cell signaling pathway in ALL
and MLL. Furthermore, the co-inhibitor LIRB3 (PIR-B) is also
relatively down-regulated in ALL which could be treated as a
positive factor for activating the B cell signaling pathway. Notably,
the relatively lower expression of Rac in ALL may play an
important role of lymphoblastic leukemia. In murine study, it has
been demonstrated that Rac genes are important for appropriate
positioning of hematopoietic stem cells (HSCs) within the bone
marrow microenvironment. The deletion of both Rac1 and Rac2
murine alleles would lead to a massive egress of HSCs into the
blood from the marrow [81,82]. Thus, we may understand the
role of B cell signaling pathway between those different groups of
leukemia. This is an example to demonstrate how multiple level-2
(in general level-k) genes can be useful to interpret the observations
and to understand the mechanisms behind. We believe that GMI
algorithm will be a useful algorithm to the community.
In the Lung Cancer data set, we select all probe sets with p-value
smaller than or equal to 0.0001 and group these probe sets into
different gene lists for different compositions of the upper group.
In the results shown in Table 4, there are five combinations in
which we can identify related pathways (EASE Score , 0.05).
These five combinations are Adeno-Normal, Adeno-SQ, Normal-
SCLC, SCLC-SQ and Normal-COID. Each of these combina-
tions belongs to the upper group. These pathways associated with
SCLC-COID list are independently tabulated in Table 5. The full
tables with probe set lists are also provided in Table S10 and Table
S11. Out of these five combinations two combinations, Adeno-SQ
and SCLC-SQ are important in order to molecularly distinguish
four classes of lung cancer. In SCLC-COID group out of 27
pathways identified, 10 pathways are directly involved in cancer as
their name suggests and additional pathways like splicesome,
phosphatidylinositol signaling, calcium signaling and cell cycle
pathways are also participatory in cancer process as discussed
earlier. Importantly, the pathways like wnt, ErbB, MAPK,
autophagy and Jak-Stat signaling are all well established in cancer
development process. However, it is presently unclear as why
Alzheimer’s, Type II Diabetes, Long-term potentiation and
Neurotrophin signaling pathways genes are up-regulated in
SCLC-COID groups since their roles in cancer are not well
founded. In the Adeno-SQ list, genes belonging to pathways of
Ribosome, ECM receptor interaction and Focal adhesion were
found to be up-regulated. Literature search revealed that all of
these pathways are more or less compromised in Adeno-SQ [83-
86].
To summarize, KEGG pathway analysis establishes that there is
as such no specific pathway(s) that can exclusively determine the
subgroups of cancer. A plethora of pathways, shared and/or non-
shared, is activated in various cancer subgroups. The level-n
discriminatory genes found by GMI are important genes that play
a major role in multiple cancer pathways.
Discussion
In this study, we emphasize the important role played by
multiple-class specific marker genes. We found that most available
gene selection algorithms focus on or tend to identify single-class
specific signature genes as marker genes. But, multiple-class specific
markers may play important roles in biology besides construction of
computational prediction systems. The lack of intuitive, easy-to-use
methodologies for biologists inspired us to propose a novel gene
selection algorithm based on an index called, Group Marker Index
(GMI), which is efficient in the identification of both single- and
multiple-classspecificsignature genesfrom microarray data.Forthe
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formulated and used along with GMI. GMI differs from template-
based methods in two aspects. First, to evaluate each gene, GMI
uses the ordering of mean gene expression values for all classes that
enables it to identify de novo certain combination of classes for each
level of discrimination. It does not need to check all combinations of
classes and hence it reduces drastically the computation overhead.
We have demonstrated that GMI can identify robust and
statistically significant marker genes for each level of discrimination
using a repeated random-splitting procedure (Table 1 and Tables
S1, S2, S3). Second, no prior knowledge is required for template
assignment. It is possible for GMI to infer novel relationships
between the studied classes/diseases. We have discussed the
relevance/biological roles played by several level 2/3 genes. In
nutshell, we observed selective dys-regulation of cytoskeleton
regulating gene-network primarily at level-2 in both CNS and lung
cancer. Secondly, we found that neuron-specific cytoskeleton genes
are aberrantly expressed in COID and SCLC tumor of lung. Third,
calcium signaling pathway genes are upregulated at level-3 of lung
tumor. This method hitherto uncovered the importance of
cytoskeleton genes and their use as class-specific markers for cancer
diagnosis. In addition, we have also mapped a group of level 2/3
genes to the KEGG pathways. Both results exhibited concordant
findings and implied potentially common properties between
different classes or cancers. It suggests the possibility of identifying
common drug targets between different diseases. It also opens up
the possibility of using a specific remedy designed for one disease to
cure another disease.
Second, GMI uses a non-parametric indicator, between-class-
transition (BCT), to evaluate the discrimination between classes rather
than evaluating the similarity between a template and gene expression
values. An advantage of exploiting discrimination ability rather than
similarity is that it ensures that the selected genes will be able to
discriminate between subsets of classes at least to a reasonable extent.
Inspired by the work in [19,20] where authors used Analysis of
Variance (ANOVA) along with the template-matching step for their
Table 4. Summarization of the identified pathways related to the level-2 discriminatory genes in the Lung Cancer data set (Part I).
Term Count % p-value Fold Enrichment Bonferroni Benjamini FDR
Adeno-Normal List
hsa05416:Viral myocarditis 10 9.0909 1.17E-07 11.5516 1.17E-05 1.17E-05 1.30E-04
hsa05330:Allograft rejection 8 7.2727 1.60E-07 18.2258 1.60E-05 7.99E-06 1.77E-04
hsa05332:Graft-versus-host
disease
8 7.2727 2.86E-07 16.8238 2.86E-05 9.55E-06 3.18E-04
hsa04940:Type I diabetes mellitus 8 7.2727 4.88E-07 15.6221 4.88E-05 1.22E-05 5.42E-04
hsa05320:Autoimmune thyroid disease 8 7.2727 1.93E-06 12.8653 1.93E-04 3.85E-05 0.0021
hsa04612:Antigen processing and presentation 9 8.1818 5.23E-06 8.8933 5.23E-04 8.71E-05 0.0058
hsa05310:Asthma 6 5.4545 2.00E-05 16.9689 0.0020 2.86E-04 0.0222
hsa04514:Cell adhesion molecules (CAMs) 9 8.1818 1.54E-04 5.5920 0.0153 0.0019 0.1711
hsa05322:Systemic lupus erythematosus 8 7.2727 1.58E-04 6.6276 0.0157 0.0018 0.1754
hsa04672:Intestinal immune network for IgA
production
6 5.4545 2.68E-04 10.0428 0.0264 0.0027 0.2966
hsa00590:Arachidonic acid metabolism 6 5.4545 5.03E-04 8.7874 0.0490 0.0046 0.5564
hsa04640:Hematopoietic cell lineage 7 6.3636 5.18E-04 6.6757 0.0505 0.0043 0.5731
hsa04142:Lysosome 7 6.3636 0.0026 4.9069 0.2279 0.0197 2.8294
hsa04210:Apoptosis 5 4.5455 0.0199 4.7136 0.8660 0.1338 19.9982
hsa04610:Complement and
coagulation cascades
4 3.6364 0.0492 4.7546 0.9936 0.2858 42.8973
Adeno-SQ List
hsa03010:Ribosome 7 14.2857 4.68E-06 14.6121 0.0002 0.0002 0.0042
hsa04512:ECM-receptor interaction 6 12.2449 6.62E-05 12.9719 0.0025 0.0013 0.0598
hsa04510:Focal adhesion 4 8.1633 0.0888 3.6141 0.9708 0.6922 56.8582
Normal-SCLC List
hsa04510:Focal adhesion 3 10.7143 0.0286 9.4869 0.4567 0.4567 20.0947
Normal-COID List
hsa04142:Lysosome 5 3.9683 3.09E-02 4.1001 9.26E-01 9.26E-01 2.85E+01
SCLC-SQ List
hsa03040:Spliceosome 12 12.5000 1.83E-08 9.6857 9.15E-07 9.15E-07 1.76E-05
hsa03030:DNA replication 8 8.3333 3.34E-08 22.6000 1.67E-06 8.36E-07 3.22E-05
hsa04110:Cell cycle 10 10.4167 2.20E-06 8.1360 1.10E-04 3.67E-05 0.0021
hsa03410:Base excision repair 6 6.2500 1.76E-05 17.4343 8.81E-04 2.20E-04 0.0170
hsa00670:One carbon pool by folate 3 3.1250 0.0100 19.0687 0.3955 0.0958 9.2400
doi:10.1371/journal.pone.0024259.t004
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expression values and class labels for each gene. We find that a gene
with a low ANOVA p-value often does not exhibit good
discrimination ability between classes. Our experience shows that
most genes in a multiple-class microarray data set are evaluated with
small p-values byANOVA test (See Fig.S5).T h u s ,f o rs u c hap r o b l e m
the main criterion used for gene selection is essentially the correlation
value. Moreover, since TBM relies on correlation, it suffers from an
additional problem (as already explained) while applying on the
microarray data with unbalanced sample sizes over different classes.
We have designed an example with unbalanced samples (Fig. 3) to
demonstrate that the class with large sample size biases the resultant
correlation value and the class with small sample size may not




SRBCT data set. It is a cDNA microarray data set with 63
samples from 4 classes of childhood small round blue cell tumors
(SRBCT): 23 Ewing sarcomas (EWS), 8 Burkitt lymphomas(BL),12
neuroblastomas (NB), and 20 rhabdomyosarcomas (RMS). Each
sample is represented by 2308 genes. This data set is available at
http://research.nhgri.nih.gov/microarray/Supplement/.
Leukemia data set. This Affymetrix high-density oligonu-
cleotide array data set has 57 samples from 3 classes of leukemia:
20 acute lymphoblastic leukemia (ALL), 17 mixed-lineage
leukemia (MLL), 20 acute myelogenous leukemia (AML), each
with 12582 genes. This data set is available at http://www.broad.
mit.edu/cgi-bin/cancer/datasets.cgi.
CNS data set. CNS is also an Affymetrix high-density
oligonucleotide microarray data set containing 42 samples dis-
tributed over 5 different types of tumors of the central nervous
system (CNS): 10 medulloblastomas (MD), 10 malignant gliomas
(MGlio), 10 atypical teratoid/rhabdoid tumors (Rhab), 8 primitive
neuro-ectodermal tumors (PNET), and 4 human cerebella tumors
(Ncer). For this data set each sample is represented by 7129 genes.
This data set is available at http://www.broad.mit.edu/cgi-bin/
cancer/datasets.cgi.
Lung Cancer data set. In this Affymetrix high-density
oligonucleotide array, we have 203 samples in 12600
Table 5. Summarization of the identified pathways related to the level-2 discriminatory genes in the Lung Cancer data set (Part II).
Term Count % p-value Fold Enrichment Bonferroni Benjamini FDR
SCLC-COID List
hsa04020:Calcium signaling pathway 55 2.0992 6.44E-06 1.8058 1.23E-03 1.23E-03 0.0080
hsa05223:Non-small cell lung cancer 24 0.9160 1.06E-05 2.5682 0.0020 1.01E-03 0.0132
hsa03040:Spliceosome 40 1.5267 1.01E-04 1.8344 0.0191 0.0064 0.1256
hsa04070:Phosphatidylinositol
signaling system
27 1.0305 1.54E-04 2.1083 0.0289 0.0073 0.1909
hsa04722:Neurotrophin
signaling pathway
39 1.4885 1.56E-04 1.8174 0.0294 0.0059 0.1941
hsa04210:Apoptosis 30 1.1450 1.89E-04 1.9926 0.0355 0.0060 0.2350
hsa05214:Glioma 24 0.9160 1.90E-04 2.2013 0.0357 0.0052 0.2363
hsa04010:MAPK signaling pathway 70 2.6718 1.95E-04 1.5149 0.0366 0.0047 0.2428
hsa05218:Melanoma 26 0.9924 1.97E-04 2.1160 0.0369 0.0042 0.2448
hsa05220:Chronic myeloid leukemia 27 1.0305 1.97E-04 2.0802 0.0370 0.0038 0.2452
hsa04110:Cell cycle 38 1.4504 4.09E-04 1.7566 0.0752 0.0071 0.5081
hsa04012:ErbB signaling pathway 29 1.1069 4.68E-04 1.9261 0.0855 0.0074 0.5806
hsa04930:Type II diabetes mellitus 19 0.7252 4.79E-04 2.3360 0.0874 0.0070 0.5937
hsa05210:Colorectal cancer 28 1.0687 6.01E-04 1.9261 0.1085 0.0082 0.7453
hsa05213:Endometrial cancer 20 0.7634 6.70E-04 2.2225 0.1201 0.0085 0.8297
hsa05200:Pathways in cancer 80 3.0534 7.56E-04 1.4094 0.1345 0.0090 0.9364
hsa05010:Alzheimer’s disease 45 1.7176 0.0011 1.5953 0.1875 0.0121 1.3434
hsa05215:Prostate cancer 28 1.0687 0.0016 1.8179 0.2646 0.0169 1.9818
hsa04720:Long-term potentiation 23 0.8779 0.0017 1.9545 0.2790 0.0171 2.1081
hsa04914:Progesterone-mediated
oocyte maturation
27 1.0305 0.0021 1.8142 0.3252 0.0195 2.5289
hsa04310:Wnt signaling pathway 41 1.5649 0.0026 1.5690 0.3949 0.0236 3.2188
hsa04114:Oocyte meiosis 32 1.2214 0.0028 1.6810 0.4135 0.0240 3.4154
hsa05222:Small cell lung cancer 26 0.9924 0.0031 1.7886 0.4524 0.0258 3.8464
hsa04622:RIG-I-like receptor
signaling pathway
23 0.8779 0.0032 1.8719 0.4533 0.0248 3.8563
hsa05212:Pancreatic cancer 23 0.8779 0.0038 1.8459 0.5188 0.0288 4.6529
hsa04140:Regulation of autophagy 14 0.5344 0.0039 2.3114 0.5298 0.0286 4.7956
hsa04630:Jak-STAT signaling pathway 41 1.5649 0.0043 1.5285 0.5645 0.0303 5.2701
doi:10.1371/journal.pone.0024259.t005
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(Adeno), 21 squamous cell lung carcinomas (SQ), 20 pulmonary
carcinoids (COID), 6 small-cell lung cancer (SCLC), and 17




For the Leukemia and CNS data sets, in the preprocessing step
the gene expression values less than 100 are raised to 100 and gene
expression values greater than 16000 are set to 16000. All gene
expression values are then subjected to a base 10 logarithmic
transformation. After that, the distribution of gene expression
values in each sample is adjusted to zero mean and unit variance.
For the SRBCT data set, we do not make any change to the gene
expression values as that had already been preprocessed in the
original data source [21]. For the Lung Cancer data set, we use the
same preprocessed data as used in the original paper [24] without
doing any additional preprocessing. For these four data sets, we
adopt the same data preprocessing protocols as used in a previous
study [1,15]. In this study, the analysis is conducted using the R
environment [87].
Group Marker Index (GMI)
Our main objective is to develop a gene evaluation index, which
we call ‘‘Group Marker Index (GMI)’’, to select biologically
significant genes for both two- and multiple-class discrimination
problems. GMI builds on the Gene Dominant/Dormant Index
(GDI) which was proposed in our earlier study. GDI is a gene
evaluation index to select two specific types of genes, i.e., dominant
and dormant genes defined in our previous study [1]. In a
multiple-class microarray data set, a dominant gene has high gene
expression values only in the samples from one specific class and
low gene expression values in the samples of the remaining classes.
Contrary to the dominant gene, a dormant gene has low gene
expression values in only one specific class and high gene
expression values in the rest of the classes. GMI is a further
refinement of GDI in two aspects: First, irrespective of the number
of classes, GDI will only evaluate two levels of discrimination (i.e.,
dominant and dormant conditions). GMI, on the other hand, will
evaluate K-1 levels of discrimination where there are K classes in a
pooled microarray experiment. Second, GDI uses the same
equation of signal-to-noise ratio (SNR) to evaluate genes, which
makes GDI sensitive to outliers, if any. We have avoided these
deficiencies by utilizing a simple yet novel intuitive concept,
referred to as Between-Class-Transition (BCT), as a further
refinement to help identify overlapping classes.
Between-Class-Transition (BCT)
Let xgsbe the gene expression value for the g
th gene in the s
th
sample, g=1 ,2 ,… ,G; s=1 ,2 ,… ,S. The s
th sample is associated
with a class label cs[ 1,2,:::,K fg . For each gene g, g=1,2,…,G,
we sort the gene expression values of the S samples in descending
order. In the sorted sequence, each gene expression value is
associated with the class label of the corresponding sample. In this
sorted sequence, if the class labels of two successive samples (gene
expression values) are different, we count it as a between-class-
transition (BCT). In this way, for each gene, we find the total
number of BCTs.
Illustration of BCT
We now illustrate BCT using a simple synthetic data set.
Consider the gene expression values of a gene for 10 samples
divided into two classes (first five samples belong to class 1 and the
rest belong to class 2) as depicted in the left panel of Fig. S6. The
sorted gene values are depicted in the right panel of Fig. S6. Here
we have projected the samples on a vertical line and represented
the two classes using two different symbols. In the right panel, the
fourth sample from class 1 is sandwiched between two samples
from class 2 and this adds two to the BCT count. In this way, the
total number of BCTs is 5. An ideal marker gene in a two-class
problem will have no outlier sample in either class, and the
discrimination between the two classes will be very easy. In such a
case the BCT value is only one (for the transition from one class to
the other). In all other cases, where there are some outlier samples
with gene expression values that overlap with the gene expression
values of the samples from the other class, the BCT value will be
larger than one. Note that, there could be BCTs even when there
is no outlier in the true sense of the word, but the classes have
overlap. With an increase in the number of overlapped samples,
the BCT value will increase. Therefore, we can use the number of
BCTs to help identify overlapped samples, and thus improve
marker gene identification.
Consider a two-class problem, as an example. Suppose for a
gene g, the samples from each class form compact clusters and the
clusters are well separated except for the gene expression value of
just one sample in one of the two classes, which is mixed with
samples from the other class. In this case, the effect of the outlier
on the standard deviation will depend on its location; in other
words, how far the outlier is from the mean of the gene expression
values among samples in that class. Thus, the effect of just one
outlier (mixed sample) on the standard deviation could be
moderate to severe. However, this is not the case with BCTs
because the number of BCTs will not depend on the location of the
outliers in the other class.
Computation of GMI
For easy understanding, Fig. 4 depicts the steps involved in the
computation of GMI, which are explained next.
Normalization. The gene expression values of each gene are
normalized in the range from 0 to 1 across samples. This step
preserves the richness in the original gene expression values for
each gene among the samples and helps us to easily visualize the
distribution of gene expression values for the discriminatory genes.
Computation of the mean value of each class for each
gene. For each gene, the mean of the gene expression values in
each class is calculated. Let the mean for gene g in class k be mgk.
Sorting of the mean values and defining of K-1 levels of
discrimination. For notational simplicity, to explain the
computation of the GMI for gene g, we ignore the index g.W e
sort mk, k=1,2,…,K (K = number of classes) in descending order.
Let the sorted mean values be mk(s); k=1 ,2 ,… ,K. Suppose m1(s) is
the mean for class C1(s). This means that the gene under
consideration is the most highly expressed in class C1(s). We shall
call a gene level-n discriminatory gene, if it can discriminate
between two groups of classes where one group has n classes in it
and the other group has the remaining (K-n) classes. Moreover, for
a level-n discriminatory gene, it is highly expressed in the group
with n classes while in the remaining K-n classes, this gene is poorly
expressed or unexpressed. Note that, if there are K classes, we can
define (K-1) levels of discrimination.
Computation of GMI for each level of discrimina-
tion. For a good marker gene with clear level-n discrimination,
there are n classes that have high gene expression values and all
other classes have low gene expression values. Therefore, we
define the set of classes with high gene expression values as ‘‘upper
group’’ and the set of remaining classes as ‘‘lower group’’. For a
Group Biomarker Identification
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groups should be well separated and the overlap between the
groups should be low. For level-n discrimination for gene g, first we
focus on the separation between upper and lower groups. We use
the difference between the mean values of classes Cn(s) and Cn+1(s),
i.e., mSep = mn(s) – mn+1(s). This is the closest separation between a
class in the upper group and a class in the lower group. We take
this as the separation between the two groups of classes. Note that,
we are not using the group mean. Next we define a measure of
overlap. For this we find the number of BCTs between these two
groups. To consider the effect of sample size, we use a weight
parameter, NS, to normalize the BCT value. Suppose Nup and Nlow
represent the total number of samples in upper and lower groups
and let NS = Min{Nup, Nlow}. Then a measure of overlap between
the two groups can be defined as OVL~No:of BCTs=NS. The
GMI value for level-n discrimination for gene g is then defined as








A high value of GMI will indicate good separation with low
overlap between the two groups.
Finding a list of group specific genes for each level of
discrimination. After calculating the GMI values of K-1 levels
of discrimination for all genes, a list of group specific genes for each
level can be obtained as follows. Every gene has K-1 GMI values.
Clearly, genes with higher GMIn values have better level-n
discriminating power between upper and lower groups. Now for a
Figure 4. Steps involved to compute GMI and to find the list of group specific genes for each level of discrimination.
doi:10.1371/journal.pone.0024259.g004
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of GMIn values. The sorted values may be denoted as GMIn(s).A
smaller rank indicates a larger GMIn value and hence a better
level-n discriminating power of the gene. From the top of the list of
sorted level-n genes, we can select a set of genes that is likely to be
biologically interesting and is expected to be useful for level-n
discrimination. Note that, the upper and lower groups associated
with different level-n genes could be completely different. At this
point, we would like to emphasize that designing of classifier or
diagnostic prediction system is not the primary objective of this
study. The main objective is to find genes that can discriminate
between two sets of diseases, not necessarily one disease verses
other. We also emphasize that the proposed scheme neither uses
pooled mean of a group of classes nor uses the pooled standard
deviation of a set of classes and hence is free from the problems of
SNR type indexes [1].
Illustration of GMI Computation
To understand the computation of the GMI value at each level
of discrimination for a given gene, we have generated a synthetic
example, which is composed of five classes of samples. As shown in
Fig. 5, there are five classes of samples and there are ten samples in
each class. The samples from different classes are labeled with
different colors. Since there are K=5 classes, we evaluate the gene
for 4 possible levels of discrimination. In Fig. 5, panel a to panel d,
represent, respectively, the computation of level-1 to level-4
discrimination of this gene. In panel a, the level-1 discrimination is
evaluated between the third class and the fourth class because they
are ranked first and second based on the descending order of the
mean of the gene expression values in the five classes. These two
highest ranked means are used to calculate mSep and this separation
is indicated by two horizontal dashed lines in green and blue. For
an easy computation of BCTs, in all four panels, the upper and
lower groups are represented using filled in and empty symbols,
respectively. Similarly, for panels b to d. For example, in panel b,
for level-2 discrimination, mSep is computed using the mean values
of class four and class five. From these figures, it is clear that this
synthetic gene is a good level-2 gene because from panel b we find
that two groups are well separated and the BCT is just 1. This is
also revealed by the GMI values of 0.150, 9.537, 0.287, and 1.925
for level-1 to level-4, respectively.
Gene selection and evaluation of statistical significance
To evaluate the statistical significance of group specific genes
identified by GMI, we perform a permutation procedure to obtain
the corresponding p- and q-values. This procedure is similar to the
method used in our previous study [1]. The necessary steps are
summarized below. Let G be the total number of genes and S be
the total number of samples.
Step 1. Gene selection. Step 1.1 Repeated random splitting.
Given a microarray data set D with K classes (xgs is the gene
expression value of gene g in sample s;1 #g #G,1 #s#S) and with
class labels (cs,1 #s#S), we randomly select 2/3rd samples from
each class as the training set TR(r) (r denotes the r
th random
selection of samples, 1#r#R).
Step 1.2 Computation of GMI and preliminary gene selection.
For each training set TR(r), we compute the GMI values for
different levels of discrimination GMIng(r) (1#n#K-1) for each gene
g. Simultaneously, we use an independent indicator Fng(r) to denote
whether the gene g is included in the list of top N1 genes (N1 genes
ranked in descending order of GMIng(r) values); Fng(r)=1 represents
‘‘true’’ and Fng(r)=0 represents ‘‘false’’.
Step 1.3 Gene selection. After R=100 times of the random
selection of samples, we average the GMI values of different levels
of discrimination, GMIng(r),1 #r#R, for each gene g as GMIng(ave)
and sum up the Fng(r) values for each gene g as Fng(sum). Note that,
Fng(sum) is the number of times (i.e., frequency) the gene g is selected
as one of the top N1 genes in R experiments. For each level of
discrimination, we select the top N2 genes with the highest
frequencies, Fng(sum). In this study, we set both N1 and N2=10.
Step 2. Permutation. We randomly permute the class labels
cs for B times. In the b
th permutation (1#b#B), we randomly select
2/3rd samples from each class as the training set TR(r)
(b) for R=100
times. For each training set TR(r)
(b), we compute GMIng(r)
(b) for




(b) for each gene g as GMIng(ave)
(b). These
GMIng(ave)
(b) are used for the calculation of p- and q-values.
Step 3. Calculation of p-values. The p-value of the
observed averaged GMI value, GMIng(ave), for a particular level










Where I(.) is an indicator function that takes the value one when
true, and zero otherwise.
Step 4. Calculation of q-values. To account for the multiple
tests being performed in the G genes, the q-value of the observed











In this study, we have performed this permutation test with
B=200 for all data sets.
Comparison with other method
In order to demonstrate the effectiveness of our GMI method in
identifying group specific genes, we propose a scheme based on the
template-based method (TBM), which is similar to the method
used in a previous work [19] for comparison. In this study, we used
Pearson’s correlation coefficient to evaluate the relation between
gene expression values and pre-assigned templates. The detailed
steps of gene selection in the proposed TBM are described below:
TBM Step 1: Repeated random splitting. For a fair
comparison with GMI, the repeated random splitting scheme is
also used here. For a given microarray data set D with K classes (xgs
is the gene expression value of gene g in sample s;1 #g#G,1 #s#S)
with class labels (cs,1 #s#S), we randomly select 2/3rd samples
from each class as the training set TR(r) (as earlier, r denotes the r
th
random selection of samples, 1#r#R).
TBM Step 2: Normalization. For each training set TR(r), the
gene expression values of every gene are normalized across
samples to [0, 1].
TBM Step 3: Identification of group specific genes for
level-n discrimination. For every gene in the training set
TR(r), K-1 levels of discrimination are defined as in the previous
section. To find group specific marker genes for level-n
discrimination, the following steps are followed:
TBM Step 3.1 Creation of template T0(r).We create a template
T0(r){0, 0, 0, … , 0}; the length of T0(r) is equal to the number of
samples in training set TR(r). Initially, every value in T0(r) is set to
zero.
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there could be many combinations (subsets) of classes for the upper
group. We denote the appropriate template for the m
th
combination (for level-n discrimination) as Tn(m)(r) and generate it
from T0(r) as follows. If the s
th sample of gene g belongs to the
upper group (i.e., in the m
th combination of classes) then the s
th
value of T0(r) is set to 1. This modified T0(r) is the template Tn(m)(r).
TBM Step 3.3 Computation of Pearson’s correlation coefficient.
Note that, for level-n, m
th combination, and sample set TR(r), the
Tn(m)(r) is fixed. Now we compute the Pearson’s correlation
coefficient for every gene g, with the template Tn(m)(r) and denote it
as Pn(m)(r)(g). For level-n we have M~ck
n combinations. Let
rnE ðÞ r ðÞg ðÞ ~max
i
Pni ðÞr ðÞg ðÞ ;i~1,...,M
  
. Now we sort the G
correlation values rnE ðÞ r ðÞg ðÞ ,g~1,...,G in descending order and
Figure 5. A 5-class synthetic example to illustrate computation of GMI. There are four levels of discrimination in the 5-class synthetic data
set. Panels (a) to (d) depict the computation of GMI values at each level of discrimination. The dotted lines in each panel indicate the two mean values
used for GMI computation in each level of discrimination. All filled samples in each panel indicate the upper group samples. The remaining open
samples in each panel indicate the lower group samples.
doi:10.1371/journal.pone.0024259.g005
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level-n as Ln(r). Thus, a typical element of the list will have two
components: the upper group (E) and the gene (g).
TBM Step 4: Gene selection. Steps 1 through 3 are
repeated for r=1toR times (here R=100) resulting in R lists of
top N1 genes, Ln(r); r=1,…,R. Let Fn(g, m) be the number of times
(frequency) with which the gene g, associated with upper group m,
appears in the R lists. This results in a list where every gene has
associated with it just one frequency and one upper group. Now,
we sort this list in descending order based on the frequencies and
select the top N2 genes from that list. Note that, each of these N2
genes will have an associated upper group. Here N1=N2=10as
used with GMI.
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